![]() |
|||||
|
![]() | |
![]() | |
![]() | |
![]() | |
![]() | |
![]() | |
![]() |
Gene: DUSP14 |
Gene summary for DUSP14 |
![]() |
Gene information | Species | Human | Gene symbol | DUSP14 | Gene ID | 11072 |
Gene name | dual specificity phosphatase 14 | |
Gene Alias | MKP-L | |
Cytomap | 17q12 | |
Gene Type | protein-coding | GO ID | GO:0006464 | UniProtAcc | O95147 |
Top |
Malignant transformation analysis |
![]() |
![]() |
Entrez ID | Symbol | Replicates | Species | Organ | Tissue | Adj P-value | Log2FC | Malignancy |
11072 | DUSP14 | PTCwithoutHT_2 | Human | Thyroid | PTC | 4.19e-13 | -6.96e-01 | 0.0419 |
11072 | DUSP14 | PTCwithoutHT_7 | Human | Thyroid | PTC | 3.75e-04 | -7.09e-01 | 0.0381 |
11072 | DUSP14 | male-WTA | Human | Thyroid | PTC | 3.79e-39 | -3.43e-01 | 0.1037 |
11072 | DUSP14 | PTC01 | Human | Thyroid | PTC | 5.74e-16 | -4.15e-01 | 0.1899 |
11072 | DUSP14 | PTC03 | Human | Thyroid | PTC | 3.07e-07 | -5.67e-01 | 0.1784 |
11072 | DUSP14 | PTC05 | Human | Thyroid | PTC | 8.44e-11 | -2.46e-01 | 0.2065 |
11072 | DUSP14 | PTC06 | Human | Thyroid | PTC | 3.50e-15 | -4.27e-02 | 0.2057 |
11072 | DUSP14 | PTC07 | Human | Thyroid | PTC | 1.36e-15 | 1.41e-01 | 0.2044 |
11072 | DUSP14 | ATC08 | Human | Thyroid | ATC | 3.04e-04 | -6.57e-01 | 0.0541 |
11072 | DUSP14 | ATC09 | Human | Thyroid | ATC | 3.94e-09 | -5.47e-01 | 0.2871 |
11072 | DUSP14 | ATC12 | Human | Thyroid | ATC | 3.23e-02 | -5.19e-01 | 0.34 |
11072 | DUSP14 | ATC13 | Human | Thyroid | ATC | 1.40e-29 | -6.08e-01 | 0.34 |
11072 | DUSP14 | ATC1 | Human | Thyroid | ATC | 2.78e-06 | -5.69e-01 | 0.2878 |
11072 | DUSP14 | ATC2 | Human | Thyroid | ATC | 5.79e-04 | -2.03e-01 | 0.34 |
11072 | DUSP14 | ATC3 | Human | Thyroid | ATC | 2.17e-03 | -5.83e-01 | 0.338 |
11072 | DUSP14 | ATC5 | Human | Thyroid | ATC | 6.16e-27 | -5.97e-01 | 0.34 |
Page: 1 2 3 4 5 6 7 |
![]() |
∗log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage. |
Top |
Malignant transformation related pathway analysis |
![]() |
![]() |
Tissue | Disease Stage | Enriched GO biological Processes |
Colorectum | AD | ![]() |
Colorectum | SER | ![]() |
Colorectum | MSS | ![]() |
Colorectum | MSI-H | ![]() |
Colorectum | FAP | ![]() |
∗Top 15 enriched GO BP terms are showed in the bar plot of each disease state in each tissue. Each row represents a significant GO biological process which is colored according to the -log10(p.adjust). |
Page: 1 2 3 4 5 6 7 8 9 |
![]() |
GO ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | Count |
GO:001631110 | Esophagus | ESCC | dephosphorylation | 251/8552 | 417/18723 | 1.26e-09 | 2.99e-08 | 251 |
GO:000647018 | Esophagus | ESCC | protein dephosphorylation | 177/8552 | 281/18723 | 3.13e-09 | 6.72e-08 | 177 |
GO:001631121 | Liver | HCC | dephosphorylation | 230/7958 | 417/18723 | 1.00e-07 | 1.96e-06 | 230 |
GO:000647021 | Liver | HCC | protein dephosphorylation | 162/7958 | 281/18723 | 1.91e-07 | 3.46e-06 | 162 |
GO:000647015 | Oral cavity | OSCC | protein dephosphorylation | 162/7305 | 281/18723 | 1.56e-10 | 4.56e-09 | 162 |
GO:00163119 | Oral cavity | OSCC | dephosphorylation | 220/7305 | 417/18723 | 6.33e-09 | 1.34e-07 | 220 |
GO:000647016 | Oral cavity | LP | protein dephosphorylation | 89/4623 | 281/18723 | 4.60e-03 | 2.93e-02 | 89 |
GO:000647010 | Prostate | BPH | protein dephosphorylation | 78/3107 | 281/18723 | 1.53e-06 | 2.63e-05 | 78 |
GO:00163118 | Prostate | BPH | dephosphorylation | 98/3107 | 417/18723 | 1.53e-04 | 1.35e-03 | 98 |
GO:000647014 | Prostate | Tumor | protein dephosphorylation | 76/3246 | 281/18723 | 2.86e-05 | 3.46e-04 | 76 |
GO:001631113 | Prostate | Tumor | dephosphorylation | 98/3246 | 417/18723 | 7.31e-04 | 5.08e-03 | 98 |
GO:000647024 | Skin | cSCC | protein dephosphorylation | 111/4864 | 281/18723 | 4.10e-07 | 7.96e-06 | 111 |
GO:001631115 | Skin | cSCC | dephosphorylation | 134/4864 | 417/18723 | 2.65e-03 | 1.50e-02 | 134 |
GO:001631116 | Thyroid | PTC | dephosphorylation | 174/5968 | 417/18723 | 1.20e-05 | 1.31e-04 | 174 |
GO:000647020 | Thyroid | PTC | protein dephosphorylation | 123/5968 | 281/18723 | 1.69e-05 | 1.77e-04 | 123 |
GO:0006470111 | Thyroid | ATC | protein dephosphorylation | 129/6293 | 281/18723 | 1.11e-05 | 1.09e-04 | 129 |
GO:001631117 | Thyroid | ATC | dephosphorylation | 179/6293 | 417/18723 | 3.88e-05 | 3.15e-04 | 179 |
Page: 1 |
![]() |
Pathway ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | qvalue | Count |
Page: 1 |
Top |
Cell-cell communication analysis |
![]() |
Ligand | Receptor | LRpair | Pathway | Tissue | Disease Stage |
Page: 1 |
Top |
Single-cell gene regulatory network inference analysis |
![]() |
TF | Cell Type | Tissue | Disease Stage | Target Gene | RSS | Regulon Activity |
∗The dot plots of a searched regulon are shown for all cell subpopulations in each disease state of each tissue based on the regulon specific score inferred using pySCENIC and by calculating the average expression. |
Page: 1 |
Top |
Somatic mutation of malignant transformation related genes |
![]() |
Hugo Symbol | Variant Class | Variant Classification | dbSNP RS | HGVSc | HGVSp | HGVSp Short | SWISSPROT | BIOTYPE | SIFT | PolyPhen | Tumor Sample Barcode | Tissue | Histology | Sex | Age | Stage | Therapy Types | Drugs | Outcome |
DUSP14 | SNV | Missense_Mutation | novel | c.350N>A | p.Arg117His | p.R117H | O95147 | protein_coding | tolerated(0.05) | probably_damaging(0.997) | TCGA-EA-A410-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Unknown | Unknown | SD |
DUSP14 | SNV | Missense_Mutation | novel | c.395T>G | p.Val132Gly | p.V132G | O95147 | protein_coding | deleterious(0) | benign(0.404) | TCGA-AA-3821-01 | Colorectum | colon adenocarcinoma | Female | >=65 | I/II | Unknown | Unknown | SD |
DUSP14 | SNV | Missense_Mutation | novel | c.244N>A | p.Pro82Thr | p.P82T | O95147 | protein_coding | deleterious(0) | probably_damaging(0.995) | TCGA-AA-3984-01 | Colorectum | colon adenocarcinoma | Female | <65 | I/II | Unknown | Unknown | SD |
DUSP14 | SNV | Missense_Mutation | novel | c.491A>C | p.Gln164Pro | p.Q164P | O95147 | protein_coding | deleterious(0.01) | benign(0.049) | TCGA-AA-A01K-01 | Colorectum | colon adenocarcinoma | Female | >=65 | III/IV | Chemotherapy | folinic | CR |
DUSP14 | SNV | Missense_Mutation | novel | c.284A>G | p.Asp95Gly | p.D95G | O95147 | protein_coding | deleterious(0.02) | benign(0.087) | TCGA-AP-A0LM-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | III/IV | Chemotherapy | cisplatin | SD |
DUSP14 | SNV | Missense_Mutation | rs368619264 | c.50N>A | p.Arg17Gln | p.R17Q | O95147 | protein_coding | tolerated(0.62) | possibly_damaging(0.602) | TCGA-AX-A0J1-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD |
DUSP14 | SNV | Missense_Mutation | rs562478056 | c.398N>A | p.Cys133Tyr | p.C133Y | O95147 | protein_coding | deleterious(0) | benign(0.274) | TCGA-AX-A1CE-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | I/II | Unspecific | Paclitaxel | SD |
DUSP14 | SNV | Missense_Mutation | novel | c.20N>A | p.Ser7Asn | p.S7N | O95147 | protein_coding | tolerated(0.47) | benign(0) | TCGA-AX-A3G9-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | III/IV | Chemotherapy | carboplatin | SD |
DUSP14 | SNV | Missense_Mutation | rs751469260 | c.454G>A | p.Val152Ile | p.V152I | O95147 | protein_coding | tolerated(0.43) | benign(0) | TCGA-B5-A11U-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | >=65 | III/IV | Unknown | Unknown | SD |
DUSP14 | SNV | Missense_Mutation | novel | c.569N>C | p.Arg190Pro | p.R190P | O95147 | protein_coding | deleterious(0.01) | possibly_damaging(0.51) | TCGA-D1-A15W-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | III/IV | Chemotherapy | taxol | SD |
Page: 1 2 3 |
Top |
Related drugs of malignant transformation related genes |
![]() |
(DGIdb 4.0) |
Entrez ID | Symbol | Category | Interaction Types | Drug Claim Name | Drug Name | PMIDs |
Page: 1 |